Blog Skip to content
Case Study: MACI Patellar & Trochlear Repair with Concomitant Tibial Tubercle Osteotomy

Case Study: MACI Patellar & Trochlear Repair with Concomitant Tibial Tubercle Osteotomy

See a recent case study to learn how an 18-year-old collegiate athlete with cartilage defects of the lateral trochlea and patella was able to resume her pole-vaulting career with MACI surgery.

Read More

Case Study: Isolated Patella Lesion Repair with Knee Cartilage Repair Surgery

Case Study: Isolated Patella Lesion Repair with Knee Cartilage Repair Surgery

See a recent case study to learn how a 38-year-old runner was able to resume her active lifestyle following isolated patella lesion repair with MACI.

Read More

Case Study: Medial Femoral Condyle Cartilage Repair

Case Study: Medial Femoral Condyle Cartilage Repair

See a recent case study for how an 18-year-old recreational athlete was able to resume her active lifestyle following an accident and left knee medial femoral condyle cartilage with MACI.

Read More

Case Study: Trochlear Defect Repair with MACI

Case Study: Trochlear Defect Repair with MACI

A recent case study shows how a 23-year-old former college athlete was able to resume snowboarding and playing basketball following trochlear defect repair with MACI surgery.

Read More

Load More

#

Sign up to receive MACI clinical education, resources to share with patients, and more.

Request more information

#

Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:
  • Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
  • Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
  • Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
  • Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:
  • Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
  • The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.